Skip to content

Study · Randomized controlled trial · n = 108 · 2026

7 results

Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.

Atieh O, Daher J, Abboud M, Wu Q, Sattar A, Baissary J, Koberssy Z, Labbato D, Eckard AR, McComsey GA

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1 May 2026Cited by 4 (Europe PMC)

PMID41098140 (opens in a new tab)DOI10.1093/cid/ciaf577 (opens in a new tab)PepBankPUB-41098140
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with HIV on antiretroviral therapy, semaglutide increased visuospatial scores more than placebo at 32 weeks.

    In plain wordsIn people with HIV, semaglutide improved visuospatial thinking scores more than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseVisuospatial score at 32 weeks
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with HIV on antiretroviral therapy, semaglutide increased naming and language scores more than placebo at 32 weeks.

    In plain wordsIn people with HIV, semaglutide improved naming and language scores more than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseNaming and language score at 32 weeks
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with HIV on antiretroviral therapy, semaglutide increased delayed recall scores more than placebo at 32 weeks.

    In plain wordsIn people with HIV, semaglutide improved delayed recall scores more than placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseDelayed recall score at 32 weeks
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, PWH on semaglutide significantly increased visuospatial, naming/language, and delayed recall scores at 32 weeks (P = .01, .05, and .04, respectively).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In people with HIV, the semaglutide effect on visuospatial score stayed significant after adjusting for sex and absolute CD4 count.

    In plain wordsIn people with HIV, semaglutide still improved visuospatial scores after adjusting for sex and CD4 count.

    Peptide
    Semaglutide
    Outcome
    IncreaseVisuospatial score after adjustment for sex and CD4 count
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In people with HIV, the semaglutide effect on naming and language scores was no longer significant after adjusting for sex and absolute CD4 count.

    In plain wordsIn people with HIV, the naming and language benefit of semaglutide was no longer significant after adjusting for sex and CD4 count.

    Peptide
    Semaglutide
    Outcome
    No significant changeNaming and language score after adjustment
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In people with HIV, the semaglutide effect on delayed recall scores was no longer significant after adjusting for sex and absolute CD4 count.

    In plain wordsIn people with HIV, the delayed recall benefit of semaglutide was no longer significant after adjusting for sex and CD4 count.

    Peptide
    Semaglutide
    Outcome
    No significant changeDelayed recall score after adjustment
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    After adjusting for sex and absolute CD4 count, only visuospatial score remained statistically significant (P = .05).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.
  7. 07HumanRandomized controlled trialMechanism

    In people with HIV, semaglutide kept a positive direct effect on visuospatial score when changes in hsCRP and soluble CD163 were taken into account.

    In plain wordsIn people with HIV, semaglutide still showed a positive direct effect on visuospatial scores after accounting for inflammation markers.

    Peptide
    Semaglutide
    Outcome
    IncreaseNatural direct effect on visuospatial score in mediation analysis
    Study

    n = 108

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneous · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    Semaglutide's total natural direct effect maintained a positive effect on the visuospatial score while accounting for potential changes in high-sensitivity C-reactive protein and soluble CD163 levels (P = .04).
    2 context sentences
    Summary · context
    In this randomized, double-blind, placebo-controlled phase 2b clinical trial, PWH on antiretroviral therapy were randomized 1:1 to receive 32 weeks of subcutaneous semaglutide or placebo.
    Summary · context
    108 participants were included (54 per arm); 65% were non-White, 40% were female, and median age was 53 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 2Results postedNCT04019197

Effects of Semaglutide in HIV-Associated Lipohypertrophy

Case Western Reserve Universityn = 10816 May 2019 to est. 1 Sept 2026

HIV/AIDS · Lipohypertrophy · Obesity

Trial pageClinicalTrials.govUpdated 4 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.